Join us for an in-depth session exploring the Orphan Drug Tax Credit (ODTC), a powerful incentive designed to support the development of treatments for rare diseases. This webinar will walk you through everything you need to know about qualifying for and leveraging the ODTC, from eligibility criteria to how it complements the more widely known R&D Tax Credit.
Agenda
- Overview of The Orphan Drug Tax Credit
- Qualification for The Orphan Drug Tax Credit
- Details about rare diseases and why treatment development is incentivized
- Calculation of the credit and how you claim
- Use case of the Orphan Drug Tax Credit
- Interaction of ODTC and RDTC
What is The Orphan Drug Tax Credit
Enacted in 1983 under the Orphan Drug Act, the Orphan Drug Tax Credit was designed to incentivize investment in new treatments for rare diseases. Multiple incentives were created to make development more financially possible. This tax credit was made permanent in 1997 and modified in 2017 under the Tax Cuts and Jobs Act. During this modification, it was reduced to capture costs from 50% of clinical expenses incurred to 25%.
About Leyton
Leyton is an international consulting firm that helps businesses leverage financial incentives to accelerate their growth and achieve sustainable performance. We simplify access to these complex incentives. Our combined teams of highly skilled Tax and Technical specialists maximize the financial benefits for businesses. With compliance always front of mind, we have been delivering optimal services for our client for over 25 years. This provides peace of mind that you will always receive the maximum benefit, without taking risks.